#Japan #Saga #Saga University #Innovacell #ICEF15

Innovacell and Saga University: Collaborative Research Breakthrough

On June 18, 2026, Innovacell, a pioneering company in regenerative medicine based in Japan, reported a significant achievement in collaboration with the Saga University Faculty of Medicine's Department of Otolaryngology and Head and Neck Surgery. The findings from this partnership were presented at the 127th Japanese Otolaryngology Head and Neck Surgery Conference.

Research Background

This collaborative research focuses on ICEF15, a cellular therapy aimed at treating urge fecal incontinence. Under the supervision of Professor Yoichiro Sugiyama from Saga University, the study explores potential new treatment indications related to swallowing disorders, also known as dysphagia. This condition occurs when patients face difficulties in swallowing food or liquids, significantly impacting their quality of life.

The presentation outlined experimental findings where autologous cultured muscle cells were surgically implanted into the thyropharyngeal muscles of mice affected by a swallowing disorder model induced via vagus nerve pharyngeal branch transection. The results showed observable improvements in swallowing function, correlating with the application of ICEF15.

Conference Presentation Details

• - Conference Name: 127th Japanese Otolaryngology Head and Neck Surgery Conference
• - Date: May 20-23, 2026
• - Presentation Title: "Evaluation of the Effect of Cultured Myoblast Cell Transplantation on Mouse Pharyngeal Constrictor Muscles"
• - Presenters: Akimitsu Minesaki, Tomoya Ishida, and Yoichiro Sugiyama from the Saga University Department of Otolaryngology and Head and Neck Surgery.

Future Implications

It is important to note that this achievement represents early-stage exploratory research in the field of regenerative medicine. The findings do not yet demonstrate the efficacy or safety of ICEF15 for clinical application, as it is still in the developmental phase and has not received regulatory approval for any indications at this time.

Innovacell aims to accelerate the research and development of innovative regenerative medicine products through partnerships with academia. The focus remains on addressing unmet medical needs in disease areas that require new treatment options.

About Innovacell

Founded in Japan in 2021, Innovacell operates as a parent company of a spin-off from the Medical University of Innsbruck in Austria. Innovacell's mission is to enhance people's health and quality of life through the commercialization of cell and regenerative therapies. The company is currently advancing clinical trials on ICEF15 across 11 European countries and Japan and has successfully completed multiple clinical trials, including late-stage Phase II trials for ICEF15 targeting urge fecal incontinence and ICES13 targeting stress urinary incontinence.

In conclusion, the collaboration between Innovacell and Saga University marks a promising step towards exploring new therapeutic avenues for patients suffering from severe swallowing disorders. The ongoing commitment to research signifies Innovacell's dedication to improving patient outcomes in fields that currently lack effective solutions.